Metastatic Colorectal Cancer
Conditions
Keywords
colorectal cancer, Kras mutation, Nras mutation, Braf mutation
Brief summary
The objective of this study is to optimize the search by next-generation sequencing (NGS) mutations in the KRAS, BRAF and NRAS on circulating tumor DNA and compare the genetic profiles obtained with those from tumors embedded in paraffin
Interventions
10 ml blood sample
Sponsors
Institut de Cancérologie de Lorraine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with metastatic or locally advanced colorectal carcinoma with a KRAS, BRAF or NRAS mutation * Age ≥ 18 years * Patient information and written informed consent form signed * Patient must be affiliated to a social security system
Exclusion criteria
* Patients whose health-cons indicates a blood sample 10mL * Age \< 18 years * Pregnant or breast feeding females * Persons deprived of liberty or under supervision
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Technical Optimization of KRAS, BRAF and NRAS mutations detection | 1 day | Optimize the detection of mutations of KRAS (exons 2, 3 et 4), NRAS (exons 2, 3 et 4) and BRAf (exon 15) genes, using the next-generation sequencing technology from circulating tumor DNA in patients with metastatic colorectal cancer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| KRAS, NRAS et BRAF mutational status | 1 day | Compare the results of KRAS NRAS and BRAF genes genotyping obtained from circulating tumor DNA to that achieved by the current gold standard (paraffin-embedded). |
Countries
France
Outcome results
None listed